AI-Powered Breakthroughs in Life Sciences

Miles Wang, an OpenAI researcher, is leaving the company to launch a new startup focused on developing AI models for drug discovery. According to sources, several other OpenAI researchers are expected to join the new company.

Wang is in talks to raise about $200 million at a $2 billion valuation, with Lightspeed potentially leading the funding round. However, Wang disputed the story's funding figures and description of the company, but did not provide specific details.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. This trend is evident in recent developments, such as Chai Discovery's $400 million raise at a $3.8 billion valuation.

As a researcher at OpenAI, Wang co-authored papers on evaluating how AI models can automate and accelerate scientific discovery.

The new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor's degree in computer science. At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

• Wang's new startup may leverage AI models to identify new drugs by predicting molecular interactions.
• The ability to find new uses for existing drugs can result in significantly faster time to revenue than developing new drugs from scratch.
• The trend of investors betting on young founders who haven't completed college is evident in Wang's background.

As the life sciences industry continues to evolve, the potential for AI-powered breakthroughs is vast. With Wang's new startup at the forefront, it will be exciting to see how AI models can be applied to make meaningful contributions in this field.